These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 16962250

  • 1. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
    Brustmann H.
    Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
    [Abstract] [Full Text] [Related]

  • 2. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
    Brustmann H.
    Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
    Brustmann H.
    Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Poly(ADP-ribose) polymerase (PARP) and DNA-fragmentation factor (DFF45): expression and correlation in normal, hyperplastic and neoplastic endometrial tissues.
    Brustmann H.
    Pathol Res Pract; 2007 Sep; 203(2):65-72. PubMed ID: 17258405
    [Abstract] [Full Text] [Related]

  • 6. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
    Brustmann H, Naudé S.
    Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
    [Abstract] [Full Text] [Related]

  • 7. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis.
    Brustmann H.
    Gynecol Oncol; 2004 Oct; 95(1):16-22. PubMed ID: 15385105
    [Abstract] [Full Text] [Related]

  • 8. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
    Yakirevich E, Sabo E, Naroditsky I, Sova Y, Lavie O, Resnick MB.
    Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
    [Abstract] [Full Text] [Related]

  • 9. B7-H4 overexpression in ovarian tumors.
    Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR.
    Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
    [Abstract] [Full Text] [Related]

  • 10. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [Abstract] [Full Text] [Related]

  • 11. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
    Cai Y, Zhai JJ, Feng BB, Duan XZ, He XJ.
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
    [Abstract] [Full Text] [Related]

  • 12. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
    Han S, Xuan Y, Liu S, Zhang M, Jin D, Jin R, Lin Z.
    Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK.
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [Abstract] [Full Text] [Related]

  • 14. Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors.
    Rodabaugh KJ, Mhawech-Fauceglia P, Groth J, Lele S, Sood AK.
    Int J Gynecol Pathol; 2007 Jan; 26(1):10-5. PubMed ID: 17197890
    [Abstract] [Full Text] [Related]

  • 15. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG.
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [Abstract] [Full Text] [Related]

  • 16. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
    Zhang C, Wang YE, Zhang P, Liu F, Sung CJ, Steinhoff MM, Quddus MR, Lawrence WD.
    Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
    [Abstract] [Full Text] [Related]

  • 17. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih IeM.
    Clin Cancer Res; 2004 Oct 01; 10(19):6432-6. PubMed ID: 15475429
    [Abstract] [Full Text] [Related]

  • 18. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas.
    Mayr D, Pannekamp U, Baretton GB, Gropp M, Meier W, Flens MJ, Scheper R, Diebold J.
    Pathol Res Pract; 2000 Oct 01; 196(7):469-75. PubMed ID: 10926324
    [Abstract] [Full Text] [Related]

  • 19. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
    Wen YH, Yee H, Goswami S, Shukla PS.
    Int J Gynecol Pathol; 2009 Mar 01; 28(2):187-92. PubMed ID: 19188814
    [Abstract] [Full Text] [Related]

  • 20. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance.
    Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Stramazzotti D, Lucarini G, Biagini G.
    Gynecol Oncol; 1995 Feb 01; 56(2):169-74. PubMed ID: 7896180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.